Zhifei Biotech (300122.SZ): Clinical trial application for modified ankara pox virus (MVA) live attenuated monkeypox vaccine accepted

Zhitong Finance App News, Zhifei Biotech (300122.SZ) issued an announcement. The company recently learned that the improved live attenuated ankara virus (MVA) monkeypox vaccine developed by the wholly-owned subsidiary Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (“Zhifeilong Koma”) has obtained a notice of acceptance of the drug clinical trial application from the State Drug Administration (acceptance number: CXSL2501083). If no negative or questioning opinions have been received from the Drug Review Center within 60 days from the date of acceptance, Zhifeilong Koma may conduct clinical trials according to the submitted plan.

The company's modified live attenuated vaccine for the Ankara Pox virus (MVA) monkeypox uses the live attenuated vaccine technology route and uses the improved Ankara Pox virus variant for vaccine production. The Ankara strain cannot be effectively replicated in human cells, does not spread or cause secondary transmission in the body, and is highly safe. The acceptance of the vaccine's clinical trial application marks a key breakthrough in the vaccine matrix for emerging infectious diseases. It is the result of the company's focus on innovative technology and enhanced core research. This breakthrough progress will not only enable the company to develop steadily over a long period of time, but will also promote the improvement of China's ability to innovate independently in the prevention and control of major infectious diseases. If this project progresses smoothly, it will further enrich the company's vaccine variety, improve the company's product layout, and strengthen the company's market position.